Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
Demo Company

Omega-3 Fatty Acid Derivative Slows Tumor Growth by Blocking Formation of New Blood Vessels

By BiotechDaily International staff writers
Posted on 18 Apr 2013
A metabolite derived from an omega-3 fatty acid slows tumor growth by blocking the development of new blood vessels (angiogenesis).

Investigators at the University of California, Davis (USA) worked with cancer cell cultures and mouse cancer models to examine the effects of omega-3 and omega-6 fatty acids on tumor growth.

They reported in the April 3, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that epoxy docosapentaenoic acid (EDP), a compound produced by the human body from the fish oil omega-3 fatty acid docosahexaenoic acid (DHA), inhibited primary tumor growth and metastasis by up to nearly 70%. The blocking of tumor growth was shown in a mouse cancer model to be due to EDP-mediated inhibition of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2)-induced angiogenesis. In cancer cell cultures, EDP also suppressed the endothelial cell migration needed for new blood vessels.

In contrast, epoxyeicosatrienoic acids (EETs), metabolites of the omega-6 fatty acid arachidonic acid (ARA), slightly increased angiogenesis and tumor progression in mice.

“EDP works by a different mechanism than many current anticancer drugs that block angiogenesis,” said first author Dr. Guodong Zhang, a postdoctoral cancer researcher at the University of California, Davis. “Our investigation opens up a new understanding of the pathways by which omega-3 fatty acids exert their biologic effects. As far as we know, EDPs are the first signaling lipids that have been discovered to have such potent anticancer effects. Researchers may be able to use EDPs as structural targets to develop stable analogs as anticancer agents.”

Related Links:
University of California, Davis



Channels

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.